Drug
Pridopidine clinical trials
Also written ACR16 and TV7820.
- studies test it
- 12
- open now
- 2
- in phase 3
- 6
- first study started
- 2008
Keep track of what changes. Save the pridopidine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
12 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2008 | 2 |
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 7
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 2
Prilenia (8) · Merit E. Cudkowicz, MD (2) · Teva Branded Pharmaceutical Products R&D, Inc. (2)
Often tested with
Tested in the same studies.
Zilucoplan (1) · AZD3241 (1) · CNM-Au8 (1) · SLS-005 (1) · Fosigotifator sodium tromethamine (1) · Fosigotifator (1) · Evetifator (1) · NUZ-001 (1)
Studies
Open first, then newest update. How each study uses pridopidine is read from its arms, and is right about nine times in ten.
Testing it · 12
- Pridopidine Phase 3 Study in Huntington's DiseaseRecruitingPhase 3PrileniaNCT07609108Written as Pridopidine
- Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALSRecruitingPhase 3PrileniaNCT07322003Written as Pridopidine
- HEALEY ALS Platform Trial - Master ProtocolActive, not recruitingPhase 2/3Merit E. Cudkowicz, MDNCT04297683Written as Pridopidine
- PRidopidine's Outcome On Function in Huntington Disease, PROOF- HDCompletedPhase 3PrileniaNCT04556656Written as Pridopidine
- A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's DiseaseCompletedPhase 2Teva Branded Pharmaceutical Products R&D, Inc.NCT00724048Written as ACR16
- A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's DiseaseCompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT00665223Written as ACR16
- HEALEY ALS Platform Trial - Regimen D PridopidineCompletedPhase 2/3Merit E. Cudkowicz, MDNCT04615923Written as Pridopidine
- A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's DiseaseTerminatedPhase 2PrileniaNCT03922711Written as Pridopidine
- Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington DiseaseCompletedPhase 2PrileniaNCT01306929Written as pridopidine
- A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's DiseaseCompletedPhase 1PrileniaNCT03019289Written as pridopidine (90 mg)
- A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's DiseaseTerminatedPhase 2PrileniaNCT02494778Written as Pridopidine
- A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's DiseaseCompletedPhase 2PrileniaNCT02006472Written as Pridopidine
Codes
What other systems call pridopidine · ClinicalTrials.gg INT004625
- MeSH (NLM) C483720pridopidineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) HD4TW8S2VKPRIDOPIDINEConfirmed FDA, NLM, Wikidata
- Wikidata Q7242858pridopidineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170349PridopidineOne source FDA
- DrugBank DB11947One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C483720 | pridopidine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | HD4TW8S2VK | PRIDOPIDINE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7242858 | pridopidine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170349 | Pridopidine | One source FDA |
| DrugBank | DB11947 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.